Toxicity management in melanoma | 45 min

(0 review)
3485
students
0
Free

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...

Free

Update on the adjuvant treatment of melanoma in 2021 | 13 min

(0 review)
3590
students
0
Free

In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...

Free

Staging melanoma and bulky palpable Stage III melanoma – is surgery necessary? | 10 min

(0 review)
3590
students
0
Free

In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....

Free

Management of in-transit melanoma in the time of active systemic therapy | 11 min

(0 review)
3590
students
0
Free

With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...

Free

Melanoma vs the double-edged sword | 47 min

(1 review)
3598
students
1
Free

Immune checkpoint inhibitors have revolutionised care for patients with advanced melanoma, with around half of patients with unresectable metastatic melanoma living to five years...

Free

Recent advances in the diagnosis and treatment of melanoma | 69 mins

(0 review)
3660
students
0
Free

In this presentation given at the Yale School of Medicine Dermatology Grand Rounds, world-leading melanoma pathologist, Prof Richard Scolyer AO, discusses: • MIA’s goals...

Free